Thus, in a phase-2 clinical trial including adults without diabetes but with overweight or obesity plus ≥ 1 weight-related coexisting condition (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease), retatrutide, a synthetic triple GLP-1, GIP, and a glucagone receptor agonist resulted in a significant reduction of systolic BP (−12.1 mmHg) and diastolic BP (−8.1 mmHg) at 48 weeks [61]. Here, GLP1R is linked to Obesity.